Easing the Burden of Long-Distance Treatment
Nine Patients Selected, Each to Receive 1.3 Million Won in Support

Korea Bristol-Myers Squibb Pharmaceutical announced on February 2 that, in partnership with the Miral Welfare Foundation, it is recruiting participants for the fourth round of the 'Recover' support program, which aims to improve the treatment environment for low-income cancer patients.

Promotional image for the cancer patient treatment environment improvement project 'Recover'. Korea Bristol-Myers Squibb Pharmaceutical.

Promotional image for the cancer patient treatment environment improvement project 'Recover'. Korea Bristol-Myers Squibb Pharmaceutical.

View original image

'Recover' is a social contribution program that provides financial support for incidental expenses such as transportation, accommodation, and meals incurred during treatment for low-income cancer patients who face difficulties in continuing treatment due to financial hardship. The program has been running for four years, funded by voluntary donations from Korea Bristol-Myers Squibb Pharmaceutical employees and a matching fund from the company.


For this fourth round, nine cancer patients with a median income below 100% who are receiving chemotherapy or radiation therapy at medical institutions outside their actual place of residence will be selected. Priority will be given to those with vulnerable social support, such as recipients of basic livelihood security, those in the next-lowest income bracket, and single-parent or grandparent-headed families. Each selected participant will receive 1.3 million won. Applications can be submitted through the Miral Welfare Foundation website until March 13.


According to the National Cancer Registration Statistics from the Ministry of Health and Welfare, as of 2023, there were approximately 2.73 million cancer patients in Korea, an increase of about 140,000 from the previous year. As of 2024, cancer treatment costs have exceeded 13 trillion won. Six out of ten cancer patients receive treatment at medical institutions in the Seoul metropolitan area, resulting in additional transportation and accommodation expenses that place a burden on patients and their families.


A representative from the Miral Welfare Foundation stated, "The purpose of Recover is to improve medical accessibility for patients who are at risk of discontinuing treatment due to financial reasons," adding, "It is providing practical help in maintaining continuity of care."



In addition to Recover, Korea Bristol-Myers Squibb Pharmaceutical also operates the 'Reboot' program, which supports young cancer survivors in returning to society after recovery.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing